Previous close | 10.21 |
Open | 9.94 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 9.94 - 10.30 |
52-week range | 9.31 - 21.00 |
Volume | |
Avg. volume | 135,131 |
Market cap | 11.929B |
Beta (5Y monthly) | -0.05 |
PE ratio (TTM) | 40.92 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.28 (2.70%) |
Ex-dividend date | 28 Sept 2023 |
1y target est | N/A |
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that Eisai submitted to the U.S. Food and Drug Administration (FDA) a Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI®) intravenous (IV) maintenance dosing. LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 "Lecanemab for Early Alzheimer's Disease: Long-Term Outcomes, Predictive Biomarkers and Novel Subcutaneous Administration" at the 16th annual Clinical Trials